🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

$KPRX welcomes Roger Goldberg, M.D., to its SAB. We look forward to the scientific insights and clinical perspectives he can bring to our development of new therapeutics for retinal diseases. ir.kiorapharma.com/news-events/pr…

$KPRX welcomes Lisa Walters-Hoffert to its Board. With her extensive biotech experience in strategic development, governance, finance, and capital markets, Lisa will be a key addition as we advance new treatments for retinal disease. ir.kiorapharma.com/news-events/pr…

Brian Strem Kiora Pharmaceuticals discusses inherited retinal diseases, how Kiora’s experimental therapy works to treat these conditions, and a recent collaboration that will help drive clinical development of its lead experimental therapy. Global Genes #RARECast globalgenes.org/raredaily/rest…

$KPRX CDO Eric Daniels, M.D., to present at the Jones Trading Healthcare Seaside Summit Mon., July 15 at 6:15 pm ET. Investors can access the latest update on our pipeline of drugs targeting retinal disease either live or by replay at the following link ir.kiorapharma.com/news-events/ir…

$KPRX is encouraging investors to submit questions to management relating to our recent investor presentation from the Jones Trading conference. In an effort to increase shareholder engagement, we're trying out the new tool offer by Say Technologies app.saytechnologies.com/kprx-2024-jones

$KPRX Our molecular photoswitch, KIO-301, was granted European Orphan Medicinal Product Designation to treat certain inherited retinal dystrophies. Orphan designation has now been achieved in US and EU ahead of our Ph 2 retinitis pigmentosa study. ir.kiorapharma.com/news-events/pr…

$KPRX Progress across all business fronts in Q2:  finalized design of Ph 2 study of KIO-301 in retinitis pigmentosa in partnership with Thea; advanced KIO-104 toward Ph 2 trial in inflammatory retinal disease; & ended quarter w/$27.8 MM, 2 + years cash. ir.kiorapharma.com/news-events/pr…

$KPRX ICYMI, view the fireside chat from the Canaccord Genuity Growth Conference between Brian Strem, Ph.D., and John Newman, Ph.D., CFA discussing KIO-301, KIO-104 and upcoming milestones for Kiora. wsw.com/webcast/canacc…

$KPRX We along with Nasdaq want to acknowledge the incredible leadership and contributions from our Chief Financial Officer, Melissa Tosca. The recent move to CFO follows the many successes in the capital markets, strategic planning, and building out the invaluable finance team.

Join us for a focused breakfast symposium dedicated to the exchange of info & insights on Inherited Retinal Diseases (IRDs). Seating is limited & registrations accepted on a first come, first served basis at bit.ly/2024IRDBreakfa… #IRD #VisionAustralia #KioraPharmaceuticals

$KPRX Tue, Oct 1 @ 10:15 EDT, our CFO Melissa Tosca will participate in the Lytham Partners Fall 2024 investor conference. We invite you to listen to a brief presentation followed by a fireside chat on the progress we're making against retinal disease. lnkd.in/gGvkgNFQ

Join Maxim's virtual Ocular Drug Development panel today at 11:00 am ET. Their research analysts sit down with executives from $BLTE, $LCTX, $OCGN & $KPRX to discuss the latest innovations in development for eye disease. Register here: m-vest.com/events/healthc….

$KPRX Today we announced approval to begin the Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa. KIO-301 is a gene mutation-agnostic small molecule that acs like a photoswitch to confer light-sensing capabilities in the presence of light. ir.kiorapharma.com/news-events/pr…

$KPRX In our Q3 results, we provided an update on our development pipeline comprised of two drug candidates entering Phase 2 trials. Balance sheet continues to provide runway beyond anticipated readouts for both studies. We invite you to read more > ir.kiorapharma.com/news-events/pr…

$KPRX - KLARITY Ph 2 Study approved to test  KIO-104 in macular edema associated w/diabetic retinopathy, non-infectious uveitis, retinal vein occlusion, or post-pseudophakic cataract surgery in up to 28 patients. Read full announcement -ir.kiorapharma.com/news-events/ne…

$KPRX We've secured a patent on a specific crystalline form of our KIO-104 compound targeting retinal inflammation. We expect this will extend protection of KIO-104 into 2043. Our Ph 2 trial for KIO-104 was approved earlier this week. Read more here - ir.kiorapharma.com/news-events/ne…

$KPRX - Our 2024 results are out. Highlights: 2 Ph 2 retinal disease trials using innovative small molecules on the brink of FPI; partnership w/Thea around KIO-301 allows us to advance both programs to readouts in 2026; cash projected into 2027. ir.kiorapharma.com/news-events/ne…

$KPRX - At ARVO 2025, we announced preclinical results demonstrating KIO-104 significantly reduced scar formation in an in vivo model of PVR. The findings further support KIO-104 as a promising candidate for inflammatory and proliferative retinal diseases. ir.kiorapharma.com/news-events/ne…

$KPRX This morning, we reported Q1 results. At a high level, we continued to prepare for two Phase 2 retinal disease clinical trials and have a projected cash runway that we've extended into late 2027. Click through to read our full announcement -ir.kiorapharma.com/news-events/ne…

$KPRX Inherited retinal diseases need global solutions. We've partnered with Senju, a leading ophthalmic co, to advance our molecular photoswitch, KIO-301, in Asia. Deal includes $1.25M upfront option fee, up to $110M in milestones + royalties. 🔗 ir.kiorapharma.com/news-events/ne…